Q1 2027 saw 16% revenue growth and 19% higher operating profit, driven by LENVIMA, DAYVIGO, and Leqembi. Key products expanded market share, new indications and reimbursement advances support outlook, and pipeline progress continues in AD and orexin platforms.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.